Technical note describes an open-source software for pre-therapy planning and dosimetry in Y-90 radioembolization, indicating its potential for research use.
The aim of this study was to describe Yttrium Radioembolization Dosimetry Evaluation (YRDose), an investigational open-source software suite for image-based activity planning and optional post-therapy dosimetry in yttrium-90 (Y-90) radioembolization. YRDose was implemented in Python as scripted modules within 3D Slicer 5.8.1. Mandatory inputs for the complete pre-therapy workflow are anatomical computed tomography (CT) and quantitative technetium-99m macroaggregated albumin single-photon emission computed tomography/CT image. Quantitative Y-90 PET/CT is optional for delivered-dose verification. The suite integrates CT-based segmentation with expert review, geometric alignment, binary-mask export, three-dimensional lung shunt fraction (LSF) calculation, compartment-based activity allocation, and mean absorbed-dose estimation using the Medical Internal Radiation Dose local energy deposition formalism. Segmentations, intermediate measurements, and final outputs are stored in a single Medical Reality Markup Language scene. The framework enabled sequential segmentation, volumetric LSF calculation, compartment mass estimation, planned activity calculation, and post-therapy mean absorbed-dose verification within the same software environment, preserving traceability and reproducibility. This technical note presents a reproducible open-source platform for Y-90 radioembolization planning and PET/CT dosimetry. YRDose provides an accessible research framework for developing, testing, and auditing image-based personalized dosimetry workflows, particularly in institutions without proprietary platforms. Formal validation remains necessary before routine clinical adoption.
No takes yet. Share an insight, caveat, or question.
Kubo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Nuclear Medicine Communications